Last reviewed · How we verify
NCT05862935
Influence of Physical Exercise as Adjuvant Treatment in Patients With Alzheimer's Disease
NA trial testing Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2 in Alzheimer Disease in 26 participants. Completed in 1 February 2023.
15 January 2023
Quick facts
| Lead sponsor | European University Miguel de Cervantes |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 26 |
| Start date | 1 June 2022 |
| Primary completion | 15 January 2023 |
| Estimated completion | 1 February 2023 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2
- Supervised Physical Activity: Phase 1
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
European University Miguel de Cervantes
Who can join
60 and older, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this non-randomized clinical trial is to assess the effects of strength training in the physical function of Alzheimer's disease (AD) patients. The main question it aims to answer are: 1. Is a basic strength training enough to improve physical function in AD patients? 2. Is an exercise intervention able to delayed the progression of the disease? 3. Is an AMRAP intervention feasible in AD patients? Participants in the exercise group will perform a 16-weeks program divided in two phases (phase 1: basic strength training; phase 2: AMRAP training). Participants in both (exercise and control) groups will receive their usual care treatments which include occupational therapy, musicotherapy, cognitive stimulation and sensory stimulation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05862935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other European University Miguel de Cervantes trials
Trials by the same sponsor.
- NCT07529743 — Multicomponent Exercise and Virtual Reality for Older Adults · NA · not yet recruiting
- NCT07248137 — Acute Effects of Exercise in Peripheral Arterial Disease Patients · NA · not yet recruiting
- NCT07180550 — Acute Effects of High-intensity Interval Aerobic and Functional Training at Different Intensities · NA · recruiting
- NCT07032168 — Lifestyle, Fitness, and Plasma Biomarkers in Healthy Young Adults · completed
- NCT06974006 — Life Monitoring for Rural Older Adults · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05862935 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European University Miguel de Cervantes
- Last refreshed: 11 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05862935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing